Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTX101 in acute migraine
NCT06728553Phase 2Completed
- Sponsor
- Manistee Therapeutics, Inc.
- Start
- Feb 2025
- Primary completion
- Jun 2025
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MTX101 in migraine (2 arms), sponsored by Manistee Therapeutics, Inc. Primary endpoint: Adverse Events at 48 hours. Started Feb 2025; status: completed.
02
Drugs
MTX101
03
Conditions
migraine
Beyond the preview
Go deeper on NCT06728553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06728553.